Well, you know I am one of the last folks on here
Post# of 36566
(Total Views: 405)
Posted On: 05/28/2020 2:33:03 PM
Well, you know I am one of the last folks on here to ever complain (sarcasm here)….
But, as each day goes by, it's getting a bit harder to think that Generex is getting approved for BARDA funding. Yes, I heard the info from Joe of no news yet, but that's been said I believe on other things only to find out the worst. From all reports, BARDA turnaround is about 2 weeks or so and it's well past that now.
I just find it strange that we have not heard anything on 3 different items of great importance - S1 for Generex that was put in a long long time ago, S1 for NGIO and funding. The S1 for NGIO has no bearing on the S1 for Generex at least from what we were told in the past I believe, so no idea what the hold up on the Generex S1 is, as last from Todd was they wanted to make sure they had all the 'info' I believe, yet records show it was modified on 2/20.
We got the PR on the Vaccine and manufacturing and everything in place and this and that and future trials which is good. But still the PR left out a ton of information. Such as what is going on with the above. What's up with the S1's and previous funding and BARDA standing and pursuing of other funding where it stands if any.
There is a lot of competition out there right now and Generex is just one fish in a big ocean. While Generex has a lot of potential, a lot of the other fish are getting more bites because they are getting more interest. Generex needs to get some of that interest and right now, it just isn't happening at least to shareholders. Maybe they are doing things behind the scenes, but if they are, they need to let their shareholders know as well. Maybe it's time for a CC sooner instead of later.
With all the potential this company has, with the products this company has, this stock should be at 3.00 - 4.00 right now. Excellagen alone should be a cash cow for the company. Then you have AE37 and the potential it has. We can go down the list of potential products and Generex should be a world class company.
But it isn't. Not yet anyways. And that's a problem that needs to be addressed.
But, as each day goes by, it's getting a bit harder to think that Generex is getting approved for BARDA funding. Yes, I heard the info from Joe of no news yet, but that's been said I believe on other things only to find out the worst. From all reports, BARDA turnaround is about 2 weeks or so and it's well past that now.
I just find it strange that we have not heard anything on 3 different items of great importance - S1 for Generex that was put in a long long time ago, S1 for NGIO and funding. The S1 for NGIO has no bearing on the S1 for Generex at least from what we were told in the past I believe, so no idea what the hold up on the Generex S1 is, as last from Todd was they wanted to make sure they had all the 'info' I believe, yet records show it was modified on 2/20.
We got the PR on the Vaccine and manufacturing and everything in place and this and that and future trials which is good. But still the PR left out a ton of information. Such as what is going on with the above. What's up with the S1's and previous funding and BARDA standing and pursuing of other funding where it stands if any.
There is a lot of competition out there right now and Generex is just one fish in a big ocean. While Generex has a lot of potential, a lot of the other fish are getting more bites because they are getting more interest. Generex needs to get some of that interest and right now, it just isn't happening at least to shareholders. Maybe they are doing things behind the scenes, but if they are, they need to let their shareholders know as well. Maybe it's time for a CC sooner instead of later.
With all the potential this company has, with the products this company has, this stock should be at 3.00 - 4.00 right now. Excellagen alone should be a cash cow for the company. Then you have AE37 and the potential it has. We can go down the list of potential products and Generex should be a world class company.
But it isn't. Not yet anyways. And that's a problem that needs to be addressed.
(2)
(0)